Ozette announces new suite of machine learning-powered computational analysis solutions.
SEATTLE–(BUSINESS WIRE)–Ozette Technologies, Inc., a technology-driven life sciences company, announces the launch of their Assay-to-Insights product, a streamlined, state-of-the-art process to explore the immune system in fresh and frozen samples. Ozette Assay-to-Insights combines three technologies developed by the company: world-class data generation at the Ozette Laboratory under Good Clinical Laboratory Practices (GCLP) guidelines; rapid computational monitoring of pre-defined biomarker endpoints using Ozette Endpoints™; and unbiased discovery and annotation of single-cell cytometry data through Ozette Discovery™. Insights generated from Ozette Endpoints™ and Ozette Discovery™ are made available through the Ozette Platform™, a cloud-based system that enables clinical teams to interact and explore cytometry data in a central dashboard.
Meet team Ozette at CYTO 2023 | May 20-24.
As the premiere cytometry conference convenes in Montréal this May at CYTO 2023, join our team for the first public look at how our single-cell infrastructure platform unlocks the full potential of modern, high-dimensional flow cytometry.
Four scientific presentations will highlight the speed, resolution, and scale of Ozette’s core technologies. You can also meet the team members who developed Ozette’s assay-to-insights solutions on the exhibition floor (booth 539) and hear directly from translational science and computational domain experts Cherie Green and Greg Finak in a commercial tutorial for a peek behind the scenes of our new product offerings.
PSBJ recognizes Ozette CEO Ali Ansary as 2023 40 Under 40 Honoree.
The Puget Sound Business Journal honored Ozette CEO Ali Ansary on its list of the top 40 dynamic leaders under the age of 40 in the business community who are moving the needle for the PNW startup ecosystem by making an impact in business, philanthropy, and their communities. Ali’s leadership and conviction inspire our team every day to remember Ozette’s ultimate goal: To accelerate scientific discovery for new therapies that improve patients’ quality of life and cure disease.
Click through to PSBJ to read the full profile on Ali and Ozette, available with subscription.
Ozette welcomes Dr. Ashley Wilson to lead State-of-the-Art Immunology Lab.
We are thrilled to welcome Ashley Wilson, PhD, who will lend her deep expertise in immunology, cell therapy, and clinical trials to help drive the next generation of high-dimensional single cell immune assays. She and her team will employ Ozette’s state-of-the-art immunology lab to accelerate and power an “assay to analysis” solution that allows Ozette and partners to realize the full potential of every immune dataset.
“I’m excited to build value through collaboration and drive rapid new breakthroughs for our industry partners, harnessing Ozette’s exciting advancements that allow us to see single-cell immune data at a new remarkable resolution and breadth within days or weeks, not months or years.” said Dr. Wilson.
Immuno-oncology pioneer Dr. Stanley Riddell joins Ozette’s Board of Directors.
We are honored to welcome world-renowned physician scientist and immuno-oncology pioneer Dr. Stanley Riddell to our Board of Directors. Dr. Riddell was the founding scientific director of the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Center and leads an innovative translational research program that has led to the first adoption of immunotherapies. He co-founded transformative biopharmaceutical companies including Juno Therapeutics (acquired by Celgene in 2018) and Lyell Immunopharma (IPO 2021).
“Ozette eliminates bottlenecks in immunotherapy research and development, accelerating the newest generation of therapies that harness the power of the immune system to treat disease. The computational and machine learning methods being developed at Ozette unlock insights across oncology, autoimmune disorders, and infectious diseases that cannot be otherwise surfaced using traditional approaches,” said Dr. Riddell. “I’m thrilled to join the Ozette team on their board as they pioneer and transform a space that is ripe for innovations.”
Ozette’s Corrie Ortega featured on Women Who Lead Biotech Panel.
Puget Sound Business Journal convened top executives in biotech to discuss the Pacific Northwest life sciences landscape, from the latest science in the pipeline, to growth strategies for the next generation of women in leadership. Leaders from Just-Evotec Biologics, Phase Genomics, SEngine Precision Medicine, and Ozette’s very own VP of Operations and Product, Corrie Ortega, shared their career insights gained along their journey from the bench to the boardroom.
BioTech Breakthrough recognizes Ozette as the 2022 overall immunology Company of the Year.
We’re honored to be named the 2022 Overall Immunology Company of the Year by BioTech Breakthrough. Ozette’s computational immune profiling tech breaks through complex, highly dimensional datasets to revolutionize our understanding of the human immune system. BioTech Breakthrough recognizes Ozette for accelerating scientific collaboration with automated and interpretable single-cell analysis at unprecedented speed, dimensionality, and annotation depth to capture the full value of single-cell immune data.
Ozette announces $26MM in series A funding.
Ozette, a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, today announced its $26MM Series A funding, led by Madrona Ventures. Other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners and Duke University.
Ozette’s AI in the battle against COVID-19.
In-depth immune profiling reveals a T regulatory signature that correlates with COVID-19 disease severity, an important finding as Treg cells are potential targets for treatment strategies and fighting severe disease.
Going beneath the surface of skin cancer.
We investigated our AI’s ability to predict treatment response to PD1 inhibiting immunotherapy in Merkel cell carcinoma and melanoma. We benchmarked our algorithmic approach against conventional analysis.